Table 2.
Prevalence of mtDNA haplogroups among LHON male patients and control individuals. Statistical analysis was performed using the Fischer’s exact test. Statistical significance was assumed at the level of p < 0.05
| mtDNA haplogroup | Patient group (n = 47) | Control group (n = 42) | p | OR | 95% CI |
|---|---|---|---|---|---|
| B | 2% | 0% | 1.000 | 2.742 a | 0.109–69.144 |
| H | 32% | 43% | 0.380 | 0.625 | 0.263–1.486 |
| HV | 2% | 2% | 1.000 | 0.891 | 0.054–14.710 |
| I | 4% | 2% | 1.000 | 1.822 | 0.159–20.854 |
| J | 11% | 17% | 0.537 | 0.595 | 0.174–2.041 |
| K | 11% | 0% | 0.057 | 11.000 a | 0.590–205.205 |
| N | 4% | 2% | 1.000 | 1.822 | 0.159–20.854 |
| T | 6% | 2% | 0.619 | 2.795 | 0.279–27.961 |
| U | 19% | 12% | 0.396 | 1.753 | 0.537–5.722 |
| V | 2% | 12% | 0.096 | 0.161 | 0.018–1.438 |
| W | 4% | 2% | 1.000 | 1.822 | 0.159–20.854 |
| X | 2% | 5% | 0.600 | 0.435 | 0.038–4.976 |
aHaldane’s correction was applied to calculate OR when one of the cells contained zero values